InsiderTrades

Form 4 for HAE HAEMONETICS CORP

Accepted 2022-05-18 00:00:00 ET · period of report 2022-05-16 · accession 0001127602-22-014976 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-05-18 2022-05-16 HAE Goldstein Dan VP, Corp. Ctrl S - Sale $56.10 -50 4,004 -1% -$2,805
D 2022-05-18 2022-05-16 HAE Goldstein Dan VP, Corp. Ctrl A - Grant — +868 4,872 +22% —
D 2022-05-18 2022-05-16 HAE Goldstein Dan VP, Corp. Ctrl A - Grant $0.00 +2,029 2,029 New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-05-16 S D 50 $56.10 4,004 D — — (F1) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) This number includes unvested RSUs previously reported.
2 Common Common Stock 2022-05-16 A A 868 — 4,872 D — — (F3) The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. (F4) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F2) This number includes unvested RSUs previously reported.
3 Derivative Non-qualified Stock Option (Right to Buy) 2022-05-16 A A 2,029 $0.00 2,029 D $57.60 · — to 2029-05-16 2,029 Common Stock (F5) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.